Close

Aurobindo Pharma receives USFDA approval for Levofloxacin Tablets

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US Food & Drug Administration to manufacture and market Levofloxacin tablets 250mg, 500mg and 750mg. Levofloxacin tablets 250mg, 500mg and 750mg are the generic equivalent of Ortho McNeil Janssen Pharmaceutical Inc’s Levaquin® tablets 250mg, 500mg and 750mg. Levofloxacin tablets are indicated for the treatment of adults with mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax. The product has a market size of approximately US$ 1.45 Billion for the twelve months ending September 2010 according to IMS.

Aurobindo would launch the product immediately after final approval. Aurobindo now has a total of 130 ANDA approvals (99 Final approvals and 31 Tentative approvals) from USFDA.

Latest stories